At present, CENPF is generally considered a potential marker of proliferation in a variety of malignant tumors, as it is elevated in various malignant tumors, such as liver cancer (Huang et al., 2021), gastric carcinoma (Chen et al., 2019), lung cancer (Li et al., 2021), breast cancer (Chen et al., 2020), prostate cancer (Shahid et al., 2019) and malignant glioma (Zhang et al., 2021) and is associated with poor prognosis in patients. The gene discussed is CENPF; the disease is prostate cancer.